DK2207779T3 - Fremgangsmåde til syntese af morpholinooligomerer - Google Patents

Fremgangsmåde til syntese af morpholinooligomerer

Info

Publication number
DK2207779T3
DK2207779T3 DK08850132.5T DK08850132T DK2207779T3 DK 2207779 T3 DK2207779 T3 DK 2207779T3 DK 08850132 T DK08850132 T DK 08850132T DK 2207779 T3 DK2207779 T3 DK 2207779T3
Authority
DK
Denmark
Prior art keywords
synthesis
morpholine oligomers
morpholine
oligomers
Prior art date
Application number
DK08850132.5T
Other languages
English (en)
Inventor
Yongfu Li
Christina Mary Josephine Fox
Matthew Dale Reeves
Dwight D Weller
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Application granted granted Critical
Publication of DK2207779T3 publication Critical patent/DK2207779T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
DK08850132.5T 2007-11-15 2008-11-14 Fremgangsmåde til syntese af morpholinooligomerer DK2207779T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98820007P 2007-11-15 2007-11-15
US98819207P 2007-11-15 2007-11-15
PCT/US2008/012804 WO2009064471A1 (en) 2007-11-15 2008-11-14 Method of synthesis of morpholino oligomers

Publications (1)

Publication Number Publication Date
DK2207779T3 true DK2207779T3 (da) 2014-07-14

Family

ID=40293764

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08850132.5T DK2207779T3 (da) 2007-11-15 2008-11-14 Fremgangsmåde til syntese af morpholinooligomerer

Country Status (13)

Country Link
EP (1) EP2207779B1 (da)
JP (3) JP5512533B2 (da)
KR (1) KR101617472B1 (da)
CN (1) CN101861318A (da)
BR (1) BR122019021332A8 (da)
CA (2) CA2884340C (da)
DK (1) DK2207779T3 (da)
ES (1) ES2479393T3 (da)
HR (1) HRP20140646T1 (da)
IL (1) IL205776A0 (da)
MX (1) MX2010004955A (da)
RU (1) RU2606627C2 (da)
WO (1) WO2009064471A1 (da)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2852549T3 (es) 2005-02-09 2021-09-13 Sarepta Therapeutics Inc Composición antisentido para tratamiento de la atrofia muscular
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
WO2010141511A2 (en) 2009-06-01 2010-12-09 Halo-Bio Rnai Therapeutics, Inc. Polynucleotides for multivalent rna interference, compositions and methods of use thereof
CA2779830C (en) 2009-11-13 2020-07-21 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
JP2013530154A (ja) 2010-05-28 2013-07-25 サレプタ セラピューティクス， インコーポレイテッド 修飾されたサブユニット間結合および／または末端基を有するオリゴヌクレオチドアナログ
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
WO2012031243A2 (en) 2010-09-03 2012-03-08 Avi Biopharma, Inc. dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
PL2623507T3 (pl) * 2010-09-30 2017-03-31 Nippon Shinyaku Co., Ltd. Pochodna kwasu morfolinonukleinowego
US20120122769A1 (en) 2010-11-12 2012-05-17 Avi Biopharma, Inc. Antisense antibacterial compounds and methods
WO2012150960A1 (en) 2011-05-05 2012-11-08 Avi Biopharma, Inc. Peptide oligonucleotide conjugates
CA2839593A1 (en) 2011-07-15 2013-01-24 Sarepta Therapeutics, Inc. Methods and compositions for manipulating translation of protein isoforms from alternative initiation start sites
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
BR112014011875B1 (pt) * 2011-11-18 2022-01-04 Sarepta Therapeutics, Inc Oligonucleotídeos funcionalmente modificados e subunidades dos mesmos
EP2785729B1 (en) 2011-11-30 2020-11-04 Sarepta Therapeutics, Inc. Oligonucleotides for treating expanded repeat diseases
AU2012345638C1 (en) 2011-11-30 2018-10-18 Sarepta Therapeutics, Inc. Induced exon inclusion in spinal muscle atrophy
PT2788487T (pt) 2011-12-08 2018-07-03 Sarepta Therapeutics Inc Análogos de oligonucleótido visando lmna humano
CN108611349A (zh) * 2011-12-28 2018-10-02 日本新药株式会社 反义核酸
CA2868174A1 (en) 2012-03-20 2013-09-26 Sarepta Therapeutics, Inc. Boronic acid conjugates of oligonucleotide analogues
CN102702265A (zh) * 2012-05-14 2012-10-03 天津特安化学科技有限公司 一种固相合成磷酰二胺吗啉代寡核苷酸及方法
US9856474B2 (en) 2013-01-16 2018-01-02 Iowa State University Research Foundation, Inc. Deep intronic target for splicing correction on spinal muscular atrophy gene
CN105228999B (zh) 2013-05-24 2021-03-02 味之素株式会社 吗啉代寡核苷酸的制备方法
IL282239B2 (en) 2013-09-05 2023-10-01 Sarepta Therapeutics Inc Antisense-induced exon2 inclusion in acid alpha-glucosidase
US9708360B2 (en) 2013-09-30 2017-07-18 Geron Corporation Phosphorodiamidate backbone linkage for oligonucleotides
RU2702424C2 (ru) 2014-03-12 2019-10-08 Ниппон Синяку Ко., Лтд. Антисмысловые нуклеиновые кислоты
WO2015175977A2 (en) 2014-05-16 2015-11-19 Geller Bruce L Antisense antibacterial compounds and methods
EP3569252B1 (en) 2014-05-19 2021-12-15 Oregon State University Antisense antibacterial compounds and methods
WO2015194520A1 (ja) 2014-06-17 2015-12-23 日本新薬株式会社 アンチセンス核酸
EP3208277A4 (en) * 2014-10-14 2018-06-13 Ajinomoto Co., Inc. Morpholino oligonucleotide manufacturing method
AU2015372560B2 (en) 2014-12-31 2021-12-02 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
US10675356B2 (en) 2015-05-19 2020-06-09 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
WO2016196670A1 (en) 2015-06-01 2016-12-08 Sarepta Therapeutics, Inc. Antisense-induced exon exclusion in type vii collagen
WO2016196897A1 (en) 2015-06-04 2016-12-08 Sarepta Therapeutics, Inc. Methods and compounds for treatment of lymphocyte-related diseases and conditions
WO2017024264A2 (en) 2015-08-05 2017-02-09 Eisai R&D Management Co., Ltd. Chiral reagents for preparation of homogeneous oligomers
EP3340967B1 (en) 2015-08-24 2024-05-22 Halo-Bio Rnai Therapeutics, Inc. Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
CN113913426B (zh) 2015-09-15 2024-08-02 日本新药株式会社 反义核酸
JP6875684B2 (ja) 2015-09-16 2021-05-26 日本新薬株式会社 筋萎縮症治療用アンチセンス核酸
WO2017062835A2 (en) 2015-10-09 2017-04-13 Sarepta Therapeutics, Inc. Compositions and methods for treating duchenne muscular dystrophy and related disorders
MX2018007307A (es) 2015-12-15 2019-03-14 Sarepta Therapeutics Inc Conjugados de peptidos y oligonucleotidos.
AU2016379402B2 (en) 2015-12-23 2023-01-12 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
AU2016379399B2 (en) 2015-12-23 2022-12-08 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
WO2017184529A1 (en) 2016-04-18 2017-10-26 Sarepta Therapeutics, Inc. Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
NZ747685A (en) 2016-04-29 2023-05-26 Sarepta Therapeutics Inc Oligonucleotide analogues targeting human lmna
SG10202101834QA (en) 2016-05-24 2021-04-29 Sarepta Therapeutics Inc Processes for preparing phosphorodiamidate morpholino oligomers
SG11201809497RA (en) 2016-05-24 2018-12-28 Sarepta Therapeutics Inc Processes for preparing phosphorodiamidate morpholino oligomers
MX383656B (es) 2016-05-24 2025-03-14 Sarepta Therapeutics Inc Procesos para preparar oligómeros de morfolino fosforodiamidato.
SG11201809494VA (en) 2016-05-24 2018-12-28 Sarepta Therapeutics Inc Pharmaceutical composition comprising eteplirsen
CN109563114B (zh) 2016-05-24 2022-08-12 萨勒普塔医疗公司 用于制备寡聚物的方法
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
JP7022079B2 (ja) * 2016-06-30 2022-02-17 サレプタ セラピューティクス， インコーポレイテッド ホスホロジアミダートモルホリノオリゴマーを調製するためのプロセス
CN109937042B (zh) * 2016-09-20 2023-06-27 科罗拉多州立大学董事会法人团体 使用亚磷酰胺化学法合成主链修饰的吗啉代寡核苷酸和嵌合体
KR102810425B1 (ko) 2016-12-19 2025-05-21 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체
HRP20240705T1 (hr) 2016-12-19 2024-08-30 Sarepta Therapeutics, Inc. Oligomerni konjugati koji preskaču egzon za mišićnu distrofiju
KR102646318B1 (ko) 2016-12-19 2024-03-12 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체
ES2994451T3 (en) 2017-04-20 2025-01-24 Atyr Pharma Inc Compositions for treating lung inflammation
EA201991450A1 (ru) 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
TWI812647B (zh) * 2017-09-25 2023-08-21 美商薩羅塔治療公司 經由速流合成以製備磷醯二胺嗎啉代寡聚物之製程
EP3697910A4 (en) 2017-10-18 2021-07-14 Sarepta Therapeutics, Inc. ANTISENSE OLIGOMER COMPOUNDS
EP3792269A4 (en) 2018-05-10 2022-06-22 Nippon Shinyaku Co., Ltd. PROCESS FOR PREPARING AN OLIGONUCLEIC ACID COMPOUND
US10765760B2 (en) 2018-05-29 2020-09-08 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
EP3806868A4 (en) 2018-06-13 2022-06-22 Sarepta Therapeutics, Inc. EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY
CN112399849A (zh) 2018-06-26 2021-02-23 日本新药株式会社 含有反义寡核苷酸的组合物及其在迪谢内肌营养不良症的治疗中的用途
TW202449155A (zh) 2018-07-27 2024-12-16 美商薩羅塔治療公司 用於肌肉萎縮症之外顯子跳躍寡聚物
SG11202104960PA (en) 2018-12-13 2021-06-29 Sarepta Therapeutics Inc Exon skipping oligomer conjugates for muscular dystrophy
GB201821269D0 (en) 2018-12-28 2019-02-13 Nippon Shinyaku Co Ltd Myostatin signal inhibitor
WO2021025899A1 (en) 2019-08-02 2021-02-11 Sarepta Therapeutics, Inc. Phosphorodiamidate morpholino oligomer pharmaceutical compositions
JP7689078B2 (ja) 2019-11-13 2025-06-05 日本新薬株式会社 オリゴ核酸化合物の製造方法
WO2021095875A1 (ja) 2019-11-13 2021-05-20 日本新薬株式会社 オリゴ核酸化合物の製造方法
MX2022007491A (es) 2019-12-19 2022-08-15 Nippon Shinyaku Co Ltd Acido nucleico antisentido que permite la omision de exones.
AU2020411964A1 (en) 2019-12-26 2022-06-16 National Center Of Neurology And Psychiatry Antisense nucleic acid that induces skipping of exon 50
PE20230237A1 (es) 2020-02-28 2023-02-07 Nippon Shinyaku Co Ltd Acidos nucleicos antisentido que inducen la omision del exon 51
WO2022006871A1 (en) * 2020-07-10 2022-01-13 Changzhou Syntheall Pharmaceuticals Co., Ltd. Processes for preparing oligonucleotides
AU2022266379A1 (en) 2021-04-28 2023-11-09 Nippon Shinyaku Co., Ltd. Method for producing oligonucleic acid compound
EP4342498A4 (en) 2021-05-13 2025-01-08 National University Corporation Chiba University ANTISENSE OLIGOMER
EP4349987A1 (en) 2021-05-28 2024-04-10 Sumitomo Pharma Co., Ltd. Antisense nucleic acid
AU2022298028A1 (en) 2021-06-23 2023-12-21 National Center Of Neurology And Psychiatry Combination of antisense oligomers
WO2023282346A1 (ja) 2021-07-08 2023-01-12 日本新薬株式会社 析出抑制剤
JPWO2023282344A1 (da) 2021-07-08 2023-01-12
IL310003A (en) 2021-07-08 2024-03-01 Nippon Shinyaku Co Ltd Nephrotoxicity reducing agent
US20240390508A1 (en) 2021-08-21 2024-11-28 Takeda Pharmaceutical Company Limited Human transferrin receptor binding peptide-drug conjugate
US20250011777A1 (en) 2021-09-03 2025-01-09 Sarepta Therapeutics, Inc. Delivery of anitsense oligomers by mirror image peptides
AU2022358322A1 (en) 2021-09-30 2024-05-16 Sarepta Therapeutics, Inc. Antisense oligonucleotides having one or more abasic units
JP2024539223A (ja) 2021-10-22 2024-10-28 サレプタ セラピューティクス， インコーポレイテッド 末梢ミエリンタンパク質２２関連疾患の処置のためのモルフォリノオリゴマー
AU2022424485A1 (en) 2021-12-27 2024-07-11 Nippon Shinyaku Co., Ltd. Method for producing oligonucleic acid compound
US20250163095A1 (en) * 2022-03-01 2025-05-22 Eisai R&D Management Co., Ltd. Bis-protected, activated guanine monomers
EP4590311A2 (en) 2022-09-21 2025-07-30 Sarepta Therapeutics, Inc. Dmd antisense oligonucleotide-mediated exon skipping efficiency
WO2024227040A1 (en) 2023-04-27 2024-10-31 Sarepta Therapeutics, Inc. Antisense oligomers for treatment of chronic kidney disease
WO2025030099A1 (en) 2023-08-02 2025-02-06 Sarepta Therapeutics, Inc. Non-canonical cell-penetrating peptides for antisense oligomer delivery
WO2025085810A2 (en) 2023-10-18 2025-04-24 Sarepta Therapeutics, Inc. Antisense oligomers for treatment of centronuclear myopathies
CN117586307B (zh) * 2024-01-19 2024-04-16 凯莱英生命科学技术(天津)有限公司 Pmo鸟苷单体的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH577464A5 (da) * 1972-09-22 1976-07-15 Ciba Geigy Ag
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
DE69033986T2 (de) * 1989-12-20 2003-03-13 Antivirals Inc., Portland Ungeladene, auf Morpholin basierende Polymere mit Chiralen, Phosphor enthaltenden Brücken zwischen den Untereinheiten
WO1991018898A1 (en) * 1990-06-01 1991-12-12 Nippon Shinyaku Co., Ltd. Nucleic acid homolog
US5510476A (en) 1994-07-07 1996-04-23 Isis Pharmaceuticals, Inc. Carbocation scavenging during oligonucleotide synthesis
UA48150C2 (uk) * 1994-11-02 2002-08-15 Ай-Сі-Ен Фармасьютикалз Похідні амінокислот або аміноспиртів, олігонуклеотид
US7790694B2 (en) * 2005-07-13 2010-09-07 Avi Biopharma Inc. Antisense antibacterial method and compound
ES2657400T3 (es) * 2006-05-10 2018-03-05 Sarepta Therapeutics, Inc. Análogos de oligonucleótidos que tienen enlaces intersubunitarios catiónicos

Also Published As

Publication number Publication date
KR101617472B1 (ko) 2016-05-02
JP2011503184A (ja) 2011-01-27
WO2009064471A1 (en) 2009-05-22
IL205776A0 (en) 2010-11-30
JP6178744B2 (ja) 2017-08-09
JP5512533B2 (ja) 2014-06-04
HRP20140646T1 (hr) 2014-09-26
EP2207779B1 (en) 2014-04-09
KR20100090681A (ko) 2010-08-16
BR122019021332A2 (da) 2015-05-26
CA2884340A1 (en) 2009-05-22
EP2207779A1 (en) 2010-07-21
BR122019021332A8 (pt) 2022-12-06
BRPI0819828A8 (pt) 2022-12-27
AU2008321409A1 (en) 2009-05-22
CA2704261C (en) 2015-05-26
CA2884340C (en) 2017-07-25
RU2606627C2 (ru) 2017-01-10
RU2010123958A (ru) 2011-12-20
JP2014159432A (ja) 2014-09-04
CN101861318A (zh) 2010-10-13
AU2008321409B2 (en) 2014-08-14
CA2704261A1 (en) 2009-05-22
ES2479393T3 (es) 2014-07-24
HK1144424A1 (en) 2011-02-18
MX2010004955A (es) 2010-06-30
JP2016196494A (ja) 2016-11-24
BRPI0819828A2 (pt) 2015-05-26

Similar Documents

Publication Publication Date Title
DK2207779T3 (da) Fremgangsmåde til syntese af morpholinooligomerer
DK2114886T3 (da) Fremgangsmåde til fremstilling af visse substituerede sulfiliminer
DK1795576T3 (da) Fremgangsmåde til fremstilling af carbonhydrider
DK2086944T3 (da) Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater
DK2431359T3 (da) Fremgangsmåde til fremstilling af diaminophenothiaziniumforbindelser
DK2307393T3 (da) Fremgangsmåde til fremstilling af apoptosepromotoren ABT-263
DK2155838T3 (da) Fremgangsmåde til fremstilling af forgrenede carbonhydrider
DK2021486T4 (da) System til fremstilling af bioorganiske forbindelser
DK2209900T3 (da) Anvendelse af bakterier til fremstillingen af bioenergi
DK3289876T3 (da) Forbindelser til behandling af cancer
DK2292607T3 (da) Fremgangsmåde til syntese af organiske forbindelser
DK1893586T3 (da) Fremgangsmåde til fremstilling af 1-alkyl-3-phenyluraciler
DK2057136T3 (da) Fremgangsmåde til syntese og/eller oprensning af diaminophenothiazinium forbindelser
DK2593449T3 (da) Fremgangsmåde til syntese af benzothiadiazolforbindelse
DK2311970T3 (da) Fremgangsmåde til fremstillingen af bioprodukter
DK2215031T3 (da) Fremgangsmåde til bearbejdning af pozzolaner
FI20075433L (fi) Prosessi haaroittuneiden hiilivetyjen valmistamiseksi
DK2029567T3 (da) Fremgangsmåde til frembringelse af benzopyran-2-ol-derivater
DK2213654T3 (da) Fremgangsmåde til fremstilling af 2-amino-5-brombenzamid derivater
DK2358732T3 (da) Fremgangsmåde til syntetisering af makrolidforbindelser
DK2160225T3 (da) Fremgangsmåde til fremstilling af krystaller
EP2019118A4 (en) METHOD FOR SYNTHETIZING THYMOSINS
DK2382232T3 (da) Fremgangsmåde til fremstilling af bivalirudin
DK2151428T3 (da) Ny fremgangsmåde til syntese af agomelatin
DK2209784T3 (da) Forbindelser til behandling af hepatitis C